Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeu
(NQ:
ALDX
)
5.290
-0.100 (-1.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
438,725
Open
5.360
Bid (Size)
5.280 (16)
Ask (Size)
5.290 (63)
Prev. Close
5.390
Today's Range
5.210 - 5.430
52wk Range
1.460 - 6.740
Shares Outstanding
58,576,350
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%
August 08, 2024
Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission.
Via
Benzinga
Performance
YTD
+49.44%
+49.44%
1 Month
-8.64%
-8.64%
3 Month
+62.77%
+62.77%
6 Month
+61.77%
+61.77%
1 Year
-12.71%
-12.71%
More News
Read More
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
August 08, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
August 07, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
June 20, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
June 13, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Host Investor Roundtable Q&A
June 12, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
May 08, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024
May 03, 2024
Via
InvestorPlace
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
April 25, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
April 18, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
April 04, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
March 28, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 05, 2024
Via
Benzinga
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
February 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
January 04, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
December 19, 2023
Via
Benzinga
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
December 19, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
December 18, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
3 Stocks at the Forefront of Personalized Medicine Trend
December 05, 2023
Via
InvestorPlace
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
November 28, 2023
Via
Benzinga
Exposures
Product Safety
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
November 27, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 01, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
